Program
eltrekibart
Also written as “LY3041658”, “Eltrekibart” and “LY3041658 (SC)”.
Its studies are mostly in Hidradenitis Suppurativa · Colitis, Ulcerative · Psoriasis, led by Eli Lilly.
Furthest: phase 2, since Jul 29, 20207 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 71 open or running | phase 2since Jul 29, 2020 | May 22, 2014 | none ahead |
- Named in Eli Lilly’s own pipeline as
Eltrekibart
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 22, 2014First study: phase 1 study in HealthyFirst studyNCT02148627 · 54 enrolled · United States
- Sep 7, 2016Phase 1 study in Skin DiseasesNCT02896868 · 60 enrolled · United States
- Jul 29, 2020Phase 2 study in Hidradenitis SuppurativaNCT04493502 · 72 enrolled · United States, Australia
- Dec 3, 2020Phase 1 study in HealthyNCT04653168 · 16 enrolled · Singapore
- Sep 14, 2023Phase 2 study in Hidradenitis SuppurativaNCT06046729 · 352 enrolled · United States, Australia, Canada and more
- Sep 13, 2024Phase 2 study in Colitis, UlcerativeNCT06598943 · 143 enrolled · United States, Argentina, Belgium and more
- Apr 16, 2026Phase 1 study in HealthyNCT07545590 · 60 enrolled · Singapore
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07545590Healthy · Singapore | 1 | Completed | Sep 22, 2026 | 60 |
| NCT06598943Colitis, Ulcerative · United States, Argentina, Belgium and more | 2 | Active, not recruiting | Aug 3, 2026 | 143 |
| NCT06046729Hidradenitis Suppurativa · United States, Australia, Canada and more | 2 | Completed | Sep 30, 2025 | 352 |
| NCT04653168Healthy · Singapore | 1 | Completed | May 28, 2021 | 16 |
| NCT04493502Hidradenitis Suppurativa · United States, Australia | 2 | Completed | Mar 15, 2022 | 72 |
| NCT02896868Skin Diseases · United States | 1 | Completed | Mar 19, 2019 | 60 |
| NCT02148627Healthy · United States | 1 | Completed | Feb 11, 2017 | 54 |
How it is read
Names in the registry
- “LY3041658”, 5 entries
- “Eltrekibart”, 2 entries
- “LY3041658 (SC)”, 1 entry
- “LY3041658 (IV)”, 1 entry
Conditions, from the studies’ own filings
- Hidradenitis Suppurativa, 2 studies
- Colitis, Ulcerative, 1 study
- Psoriasis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.